133 related articles for article (PubMed ID: 35354759)
1. Therapeutic Strategy for Heart Failure with Reduced Ejection Fraction and Cardiac Amyloidosis.
Imamura T; Izumida T; Nakamura M; Kinugawa K
Int Heart J; 2022; 63(2):408-410. PubMed ID: 35354759
[TBL] [Abstract][Full Text] [Related]
2. Combination therapy using tafamidis and neurohormonal blockers for cardiac amyloidosis and a reduced ejection fraction: a case report.
Imamura T; Izumida T; Hori M; Tanaka S; Kinugawa K
J Int Med Res; 2022 Jul; 50(7):3000605221078484. PubMed ID: 35904051
[TBL] [Abstract][Full Text] [Related]
3. CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis.
O'Meara E; McDonald M; Chan M; Ducharme A; Ezekowitz JA; Giannetti N; Grzeslo A; Heckman GA; Howlett JG; Koshman SL; Lepage S; Mielniczuk LM; Moe GW; Swiggum E; Toma M; Virani SA; Zieroth S; De S; Matteau S; Parent MC; Asgar AW; Cohen G; Fine N; Davis M; Verma S; Cherney D; Abrams H; Al-Hesayen A; Cohen-Solal A; D'Astous M; Delgado DH; Desplantie O; Estrella-Holder E; Green L; Haddad H; Harkness K; Hernandez AF; Kouz S; LeBlanc MH; Lee D; Masoudi FA; McKelvie RS; Rajda M; Ross HJ; Sussex B
Can J Cardiol; 2020 Feb; 36(2):159-169. PubMed ID: 32036861
[TBL] [Abstract][Full Text] [Related]
4. Misconceptions and Facts about Heart Failure with Reduced Ejection Fraction.
Krittanawong C; Rodriguez M; Lui M; Misra A; Tang WHW; Bozkurt B; Yancy CW
Am J Med; 2023 May; 136(5):422-431. PubMed ID: 36740210
[TBL] [Abstract][Full Text] [Related]
5. Effects of Cardiac Resynchronization Therapy on Cardiac Remodeling and Contractile Function: Results From Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE).
St John Sutton M; Cerkvenik J; Borlaug BA; Daubert C; Gold MR; Ghio S; Chirinos JA; Linde C; Ky B
J Am Heart Assoc; 2015 Sep; 4(9):e002054. PubMed ID: 26363005
[TBL] [Abstract][Full Text] [Related]
6. Trajectories of Left Ventricular Ejection Fraction After Acute Decompensation for Systolic Heart Failure: Concomitant Echocardiographic and Systemic Changes, Predictors, and Impact on Clinical Outcomes.
Albert J; Lezius S; Störk S; Morbach C; Güder G; Frantz S; Wegscheider K; Ertl G; Angermann CE
J Am Heart Assoc; 2021 Feb; 10(3):e017822. PubMed ID: 33496189
[TBL] [Abstract][Full Text] [Related]
7. Cardiac resynchronization induces major structural and functional reverse remodeling in patients with New York Heart Association class I/II heart failure.
St John Sutton M; Ghio S; Plappert T; Tavazzi L; Scelsi L; Daubert C; Abraham WT; Gold MR; Hassager C; Herre JM; Linde C;
Circulation; 2009 Nov; 120(19):1858-65. PubMed ID: 19858419
[TBL] [Abstract][Full Text] [Related]
8. Wall stress determines systolic and diastolic function--Characteristics of heart failure.
Alter P; Koczulla AR; Nell C; Figiel JH; Vogelmeier CF; Rominger MB
Int J Cardiol; 2016 Jan; 202():685-93. PubMed ID: 26454537
[TBL] [Abstract][Full Text] [Related]
9. Left ventricular systolic dysfunction precipitated by verapamil in cardiac amyloidosis.
Pollak A; Falk RH
Chest; 1993 Aug; 104(2):618-20. PubMed ID: 8339658
[TBL] [Abstract][Full Text] [Related]
10. Safety and Tolerability of Neurohormonal Antagonism in Cardiac Amyloidosis.
Aimo A; Vergaro G; Castiglione V; Rapezzi C; Emdin M
Eur J Intern Med; 2020 Oct; 80():66-72. PubMed ID: 32475765
[TBL] [Abstract][Full Text] [Related]
11. Doppler Echocardiography-Guided Heart Rate Modulation Therapy Using Ivabradine in a Patient with Systolic Heart Failure.
Imamura T; Kinugawa K
Medicina (Kaunas); 2022 Jan; 58(2):. PubMed ID: 35208489
[TBL] [Abstract][Full Text] [Related]
12. Impact of optimal heart rate on left ventricular reverse remodeling and functional improvement in patients with systolic heart failure.
Izumida T; Imamura T; Ueno Y; Tanaka S; Kataoka N; Nakamura M; Kinugawa K
Heart Vessels; 2021 Nov; 36(11):1688-1693. PubMed ID: 33956182
[TBL] [Abstract][Full Text] [Related]
13. Mild systolic dysfunction in heart failure (left ventricular ejection fraction >35%): baseline characteristics, prognosis and response to therapy in the Vasodilator in Heart Failure Trials (V-HeFT).
Carson P; Johnson G; Fletcher R; Cohn J
J Am Coll Cardiol; 1996 Mar; 27(3):642-9. PubMed ID: 8606276
[TBL] [Abstract][Full Text] [Related]
14. Usefulness of pulsed tissue Doppler imaging for evaluating systolic and diastolic left ventricular function in patients with AL (primary) amyloidosis.
Koyama J; Ray-Sequin PA; Davidoff R; Falk RH
Am J Cardiol; 2002 May; 89(9):1067-71. PubMed ID: 11988197
[TBL] [Abstract][Full Text] [Related]
15. The impact of right ventricular dysfunction on the effectiveness of beta-blockers in heart failure with preserved ejection fraction.
Harada D; Asanoi H; Noto T; Takagawa J
J Cardiol; 2020 Oct; 76(4):325-334. PubMed ID: 32475652
[TBL] [Abstract][Full Text] [Related]
16. Association of the frontal QRS-T angle with adverse cardiac remodeling, impaired left and right ventricular function, and worse outcomes in heart failure with preserved ejection fraction.
Selvaraj S; Ilkhanoff L; Burke MA; Freed BH; Lang RM; Martinez EE; Shah SJ
J Am Soc Echocardiogr; 2014 Jan; 27(1):74-82.e2. PubMed ID: 24075945
[TBL] [Abstract][Full Text] [Related]
17. The effect of reverse remodeling on long-term survival in mildly symptomatic patients with heart failure receiving cardiac resynchronization therapy: results of the REVERSE study.
Gold MR; Daubert C; Abraham WT; Ghio S; St John Sutton M; Hudnall JH; Cerkvenik J; Linde C
Heart Rhythm; 2015 Mar; 12(3):524-530. PubMed ID: 25460860
[TBL] [Abstract][Full Text] [Related]
18. The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial.
Cleland JG; Teerlink JR; Senior R; Nifontov EM; Mc Murray JJ; Lang CC; Tsyrlin VA; Greenberg BH; Mayet J; Francis DP; Shaburishvili T; Monaghan M; Saltzberg M; Neyses L; Wasserman SM; Lee JH; Saikali KG; Clarke CP; Goldman JH; Wolff AA; Malik FI
Lancet; 2011 Aug; 378(9792):676-83. PubMed ID: 21856481
[TBL] [Abstract][Full Text] [Related]
19. Current patterns of beta-blocker prescription in cardiac amyloidosis: an Italian nationwide survey.
Tini G; Cappelli F; Biagini E; Musumeci B; Merlo M; Crotti L; Cameli M; Di Bella G; Cipriani A; Marzo F; Guerra F; Forleo C; Gagliardi C; Zampieri M; Carigi S; Vianello PF; Mandoli GE; Ciliberti G; Lichelli L; Mariani D; Porcari A; Russo D; Licordari R; Ponziani A; Porto I; Perfetto F; Autore C; Rapezzi C; Sinagra G; Canepa M
ESC Heart Fail; 2021 Aug; 8(4):3369-3374. PubMed ID: 33988312
[TBL] [Abstract][Full Text] [Related]
20. Pathophysiology of systolic and diastolic heart failure.
Chatterjee K
Med Clin North Am; 2012 Sep; 96(5):891-9. PubMed ID: 22980053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
